Omics: Account for the 'dark matter' of biology.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Imagining the future of optical microscopy: everything, everywhere, all at once.Communications biology · 2023
   Review
2. User-friendly bioorthogonal reactions click to explore glycan functions in complex biological systems.The Journal of clinical investigation · 2023
   Article
3. Journal of the American Society for Mass Spectrometry · 2022
   Article
4. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.Nature reviews. Drug discovery · 2021
   Review
5. Biological roles of glycans.Glycobiology · 2017
   Review
6. Omics on bioleaching: current and future impacts.Applied microbiology and biotechnology · 2015
   Review

Corrections and comments

• Comment on
  DNA: Celebrate the unknowns.2013

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as